The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.

SciFest, Ireland’s largest and most inclusive STEM fair programme for second-level students, has announced its return ahead ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. My name is Tawanda, and I will be your ...

Thinkhat attends the Precision Medicine World Conference (PMWC) and unveils the first of its AI-driven healthcare and life science (HLS) p ...

A new in-person science and engineering research fair for middle school students from Westchester, Rockland and Putnam counties will premier on Saturday, April 26 at Edgemont High School. The ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...

Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") .  Such investors are advised to contact Danielle Peyton at ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., Appeal Nos. 2024-1965, -1966, -2082, -2083 (Fed. Cir. Jan. 29, 2025) ...